Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Cantor Fitzgerald initiated coverage of GH Research (GHRS) with an Overweight rating and $14 price target Maximize Your Portfolio with Data ...

Key Insights GH Research's significant insider ownership suggests inherent interests in company's expansion A total ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

As of September 2024, GH Research had $193 million in cash but expects that by the end of December, the cash will likely be roughly $182 million. The company has an accumulated deficit of $97 million.

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research (GHRS – Research Report), with a price ...

Owens & Minor, Inc. OMI shares dropped 32% to $9.68 after the company issued lower-than-expected fourth-quarter and FY24 ...

The company earlier announced that the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase IIb ...

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.